Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Mipsagargin||G-202||Mipsagargin (G-202) is a prodrug that is activated in prostate specific membrane antigen (PSMA)-positive cells, resulting in apoptosis in tumor cells (PMID: 27115568, PMID: 31212948).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||hepatocellular carcinoma||not applicable||Mipsagargin||Phase II||Actionable||In a Phase II trial, Mipsagargin (G-202) demonstrated safety in hepatocellular carcinoma patients who failed prior Nexavar (sorafenib) therapy, and resulted in a median time to tumor progression of 134 days, median progression-free survival of 129 days, and median overall survival of 205 days, with 63.2% (12/19) of patients achieving stable disease, and no complete or partial responses observed (PMID: 31212948; NCT01777594).||31212948|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02607553||Phase II||Mipsagargin||Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA||Completed|
|NCT02067156||Phase II||Mipsagargin||Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma||Completed|
|NCT02381236||Phase II||Mipsagargin||G-202 in the Neoadjuvant Setting Followed by Radical Prostatectomy in Patients With Prostate Cancer||Completed|
|NCT02876003||Phase II||Mipsagargin||Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma||Withdrawn|